Bim [1C2C8] Antibody from MYBIOSOURCE INC.
Search, find, compare suppliers for anti-Bim [1C2C8] antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | Bim [1C2C8] |
| Clone | [1C2C8] |
| Host Species | Mouse |
| Reactive Species | human, mouse |
| Isotype | IgG1 |
| Format | immunoaffinity purified |
| Size | 0.1 mg |
| Concentration | 1 mg/mL |
| Applications | ELISA (EIA), Western Blot (WB), Immunocytochemistry (ICC), Immunofluorescence (IF) |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | Bim Monoclonal Antibody: Members in the Bcl-2 family are critical regulators of apoptosis by either inhibiting or promoting cell death. Bcl-2 homology 3 (BH3) domain is a potent death domain. BH3 domain containing pro-apoptotic proteins, including Bad, Bax, Bid, Bik, and Hrk, form a growing subclass of the Bcl-2 family. Bim is another BH3 domain containing protein which can induce apoptosis. Bim interacts with diverse members in the pro-survival Bcl-2 sub-family including Bcl-2, Bcl-xL and Bcl-w. The messenger RNA of Bim is ubiquitously expressed in multiple tissues and cell lines. |
| Immunogen | Immunogen: Mouse monoclonal Bim antibody was raised against a recombinant protein corresponding to amino acids 2 to 198 of human Bim. Buffer: Bim Monoclonal Antibody is supplied in PBS containing 0.02% sodium azide. |
| Other Names | [Bim [1C2C8] : BAM; BIM; BOD; BCL2-like 11 (apoptosis facilitator)], [BCL2L11; BCL2L11; BAM; BIM; BOD; BIM; Bcl2-L-11] |
| Gene, Accession # | [BCL2L11], Gene ID: 10018, NCBI: NP_619527, UniProt: O43521 |
| Catalog # | MBS150041 |
| Price | $375 |
| Order / More Info | Bim [1C2C8] Antibody from MYBIOSOURCE INC. |
| Product Specific References | n/a |
MYBIOSOURCE INC.
MYBIOSOURCE INC.
P.O. Box 153308
San Diego CA 92195-3308
P: 1.858.633.0165
P: 1.888.MBS.0165 (1.888.627.0165) (US & Canada)
F: 1.858.633.0166
sales@mybiosource.com
http://www.MyBioSource.com
Profile of MYBIOSOURCE INC.
Return to Antibodies